Selegiline is a hypoglycemic agent for the treatment of type 2 diabetes mellitus, and in conjunction with the instructions, the excretion of selegiline is mainly through the kidneys, and the dosage needs to be reduced in patients with moderate to severe renal impairment and those who require hemodialysis or peritoneal dialysis. In order to achieve plasma concentrations of the product in patients with renal insufficiency similar to those in patients with normal renal function, the dose for patients with moderate renal insufficiency (glomerular filtration rate of 30-45 ml/min) is 50 mg once daily. In patients with severe renal insufficiency (glomerular filtration rate 15-30 ml/min) and end-stage renal disease (glomerular filtration rate <15 ml/min), as well as patients requiring hemodialysis or peritoneal dialysis, the dose is 25 mg once daily. Adverse reactions such as diarrhea, nausea, vomiting, nasopharyngitis, and headache may occur in a small number of patients taking selegiline. Deterioration of renal function, including acute renal failure, may occur with selegiline during monotherapy or combination therapy with other antihyperglycemic agents, sometimes requiring dialysis treatment. Selegiline should not be used for the treatment of patients with type 1 diabetes mellitus or diabetic ketoacidosis, in addition to hypersensitivity to the components of the product, suffering from pancreatitis or pregnant women need to be prohibited. Selegiline must be used under the guidance of a doctor, remember not to blindly use their own medicine, so as not to cause adverse consequences.